There is a critical unmet need for an innovative therapeutic drug-delivery platform that demonstrates unique capability to preferentially target bioactive disease sites safely and effectively. There is an even greater need for a platform that can overcome restrictive barriers that typify many diseases (e.g., tumor microenvironments, fibrosis, etc.) and limit treatment efficiency. Next generation platforms must also be highly versatile (e.g., allogeneic, manufacturable, bio bankable, and easily distributable) to meet the needs of patients across a wide range of diseases. The Cargocyte is an innovative platform that addresses these recognized needs and offers great promise to change the practice of modern medicine.